News

Electronic solutions such as IVR systems, PDAs, and digital pens exhibit advantages over paper and pencil in PRO data collection.

PHT company profile

BioResearch Monitors Company Profile

Tools for Clinical Trials Professionals

A comprehensive list of Web sites that contain trial and registry information for both professionals and potential participants

Exhibitor Profiles from the DIA meeting hall

EU (European Commission and EMEA) and FDA agree on guiding principles for joint FDA EMEA voluntary genomic data submission briefing meetings

The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation.

Averion Expands Operations to Europe and Names John Shillingford, PhD as President of New Wholly-Owned Subsidiary Averion GmbH

PAREXEL International Corporation a today announced that its technology subsidiary Perceptive Informatics, Inc. has been selected by Astellas Pharma Europe Limited

Images

Laboratories

A welcome letter from ACT's Publisher Wayne Blow

Other Services & Products

Contract Research Organizations

Index of Companies

Valuable resources on the Internet for clinical trial professionals and potential participants.

Contract Research Services

Subject Recruitment

Institutional Review Boards

Consulting

Laboratory Supplies

Paris, May 3, 2006– BioAlliance Pharma SA (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that its new, wholly owned sales and marketing subsidiary, Laboratoires BioAlliance Pharma SAS, has begun formal operations. Laboratoires BioAlliance Pharma will be responsible for all BioAlliance sales and marketing activities, initially focused on the launch of the company's first product Loramyc(R), for treatment of oropharyngeal candidiasis, an oral fungus found in association with immune compromised patients. Following regulatory approval expected in late 2006, the product will be launched first in France, followed by additional launches in other selected European countries as approvals are obtained under the mutual recognition procedure. The company filed for Loramyc marketing authorization approval (MAA) in September 2005. The new subsidiary will be headed by BioAlliance Pharma CEO, Dominique Costantini, MD. Florence Dupr?, vice president of sales and marketing and Alain Maquin, Head Pharmacist are the other directors.

Information Technology

ACRS and DCI Merge to Form New eCRO Services Provider ??? BANNOCKBURN, Ill. and MARIETTA, Ga., May 2 /PRNewswire/ -- Advanced Clinical Research Services, LLC (ACRS) and Data Capture International, Inc. (DCI) announced their recent merger to offer eCRO services - enhanced biometrics services using technology enabled tools and platforms - to pharmaceutical and biotechnology companies that are performing clinical trials to meet regulatory submission requirements for the US Food and Drug Administration and other global agencies. ACRS has provided clinical data management services since 1994 and has built an exceptional reputation for quality and customer service. The company's clinical data management system (CDMS) is built on an Oracle Clinical(R) platform, and has been used in providing services for more than two-hundred clinical trials in nine therapeutic areas. ACRS's client base includes large and small pharmaceutical firms as well as biotechnology companies. DCI, founded in 2002, is an Application Service Provider that offers Electronic Data Capture (EDC) software solutions and services to pharmaceutical companies and Contract Research Organizations that perform early stage human clinical trials. With the SureLynx(TM) technology platform, DCI is becoming a recognized leader as a provider of technology enhanced clinical data management solutions.

Selected oncology Web sites to assist readers in becoming more informed about cancer and available clinical trials in this therapeutic area.

Lance Armstrong to Receive Special Recognition Award on Monday, June 5

Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions, with an initial focus on peptide delivery.